243 related articles for article (PubMed ID: 15094745)
1. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
Bone Marrow Transplant; 2004 Jun; 33(12):1201-8. PubMed ID: 15094745
[TBL] [Abstract][Full Text] [Related]
2. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
[TBL] [Abstract][Full Text] [Related]
3. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
5. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
[TBL] [Abstract][Full Text] [Related]
7. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
10. Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia.
Lambertenghi Deliliers G; Annaloro C; Della Volpe A; Oriani A; Mozzana R; Pozzoli E; Tagliaferri E; Soligo D
Haematologica; 1995; 80(2):136-41. PubMed ID: 7628752
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for acute myeloid leukemia.
Linker CA
Bone Marrow Transplant; 2003 May; 31(9):731-8. PubMed ID: 12732879
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
13. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Fung HC; Stein A; Slovak Ml; O'donnell MR; Snyder DS; Cohen S; Smith D; Krishnan A; Spielberger R; Bhatia R; Bhatia S; Falk P; Molina A; Nademanee A; Parker P; Rodriguez R; Rosenthal J; Sweetman R; Kogut N; Sahebi F; Popplewell L; Vora N; Somlo G; Margolin K; Chow W; Smith E; Forman SJ
Biol Blood Marrow Transplant; 2003 Dec; 9(12):766-71. PubMed ID: 14677116
[TBL] [Abstract][Full Text] [Related]
14. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
15. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum W; Bolwell BJ; Phillips G; Farag SS; Lin TS; Avalos BR; Penza SL; Marcucci G; Byrd JC; Kalaycio ME; Sobecks RM; Pohlman B; Brown S; Elder PJ; Copelan EA
Biol Blood Marrow Transplant; 2006 Jan; 12(1):61-7. PubMed ID: 16399569
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
18. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience.
Reiffers J; Stoppa AM; Attal M; Michallet M; Marit G; Blaise D; Huguet F; Corront B; Cony-Makhoul P; Montastruc M
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):17-9. PubMed ID: 8099731
[TBL] [Abstract][Full Text] [Related]
20. The role of autologous transplantation for acute myeloid leukemia in first and second remission.
Linker C
Best Pract Res Clin Haematol; 2007 Mar; 20(1):77-84. PubMed ID: 17336257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
